Oragenics logo
Oragenics OGEN
$ 0.16 -5.88%
report update icon

Quarterly report 2026-Q3
added 11-12-2026

Oragenics Revenue | OGEN

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Oragenics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
- - 37.7 K 132 K 87 K - - - - - 1.18 M 940 K 1.03 M 1.33 M 1.44 M 1.31 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.44 M 37.7 K 832 K

Quarterly Revenue Oragenics

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - - - - 7.47 K 13.2 K 17 K - 86 K 30.4 K 15.1 K - - - - - - - - - - - - - - - - - - - - - - - - 240 K 330 K 242 K 364 K 221 K 201 K 304 K 215 K 435 K 253 K 168 K 176 K 431 K 264 K 256 K 381 K 397 K 350 K 348 K 350 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
435 K 7.47 K 234 K

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Puma Biotechnology Puma Biotechnology
PBYI
228 M $ 7.05 -1.05 % $ 353 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
80 M $ 3.69 -0.67 % $ 281 M usaUSA
Geron Corporation Geron Corporation
GERN
237 K $ 0.87 -4.76 % $ 580 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
186 M $ 11.54 -5.18 % $ 7.95 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
175 M $ 4.65 -8.46 % $ 339 M usaUSA
Genmab A/S Genmab A/S
GMAB
10.1 B $ 50.36 -1.93 % $ 3.26 B danmarkDanmark
Gossamer Bio Gossamer Bio
GOSS
48.5 M $ 10.69 -4.81 % $ 2.44 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
7.21 B $ 8.14 -0.73 % $ 5.53 B spainSpain
Liquidia Corporation Liquidia Corporation
LQDA
158 M $ 54.39 -3.96 % $ 4.68 B usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
32.7 B $ 47.8 -0.05 % $ 194 B britainBritain
MediciNova MediciNova
MNOV
410 K $ 1.3 2.36 % $ 63.8 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
1.73 B $ 56.23 -3.59 % $ 4.47 B usaUSA
Pulmatrix Pulmatrix
PULM
7.81 M $ 1.24 -12.34 % $ 4.53 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
29.3 K $ 1.05 -3.67 % $ 70.7 M germanyGermany
Immunome Immunome
IMNM
6.94 M $ 15.69 -5.54 % $ 1.37 B usaUSA
Immuron Limited Immuron Limited
IMRN
7.29 M $ 0.9 5.87 % $ 208 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
5.14 B $ 114.5 -1.19 % $ 22.4 B usaUSA
INmune Bio INmune Bio
INMB
50 K $ 0.82 -8.41 % $ 20.3 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
326 B $ 14.88 0.24 % $ 12.4 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
14.3 B $ 920.38 -0.22 % $ 96.3 B usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
203 M $ 26.58 -2.37 % $ 4.25 B usaUSA
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
47.7 M $ 4.68 -0.53 % $ 757 M usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
3.89 M $ 2.73 -9.61 % $ 22.2 M usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
67.7 M $ 10.02 5.24 % $ 1.09 B usaUSA
Adagene Adagene
ADAG
7.67 M $ 1.8 -10.56 % $ 106 M chinaChina
Denali Therapeutics Denali Therapeutics
DNLI
331 M $ 18.43 1.29 % $ 3.18 B usaUSA
Pfizer Pfizer
PFE
62.6 B $ 27.4 -0.62 % $ 156 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
214 M $ 10.56 -6.26 % $ 4.38 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
27.6 M $ 11.08 -0.81 % $ 100 M usaUSA
Editas Medicine Editas Medicine
EDIT
40.5 M $ 1.63 -4.68 % $ 145 M usaUSA
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
678 M $ 93.83 0.32 % $ 6.96 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
54 M $ 27.54 -4.24 % $ 1.6 B usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
2.38 B $ 68.45 1.08 % $ 29.4 B usaUSA
Equillium Equillium
EQ
41.1 M $ 1.06 -5.36 % $ 60.7 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
70 M $ 1.32 -5.04 % $ 75.1 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
5.82 M $ 2.42 -1.17 % $ 128 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
1.07 B $ 17.1 -2.79 % $ 2.88 B usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
1.76 K $ 1.6 -8.86 % $ 13.8 M usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
263 K - -7.31 % $ 49 M usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
190 M $ 112.31 -3.84 % $ 7.3 B usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
13.2 M - - $ 1.77 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
81.4 M $ 1.29 -2.28 % $ 164 M schweizSchweiz
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
868 M $ 32.58 -1.21 % $ 1.87 B usaUSA
Ardelyx Ardelyx
ARDX
407 M $ 2.99 -2.25 % $ 721 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
236 M $ 0.39 -8.41 % $ 100 M usaUSA
Alector Alector
ALEC
21 M $ 2.34 1.52 % $ 241 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
1.18 M $ 1.06 3.43 % $ 56.9 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
3.02 B $ 21.12 -1.26 % $ 6.62 B usaUSA